NDUFA6
ENSG00000184983
Target class
Enzyme
Chromosome
22
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFA6
- Gene name
- NADH:ubiquinone oxidoreductase subunit A6
- Gene symbol
- NDUFA6
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 (Complex I-B14) (CI-B14) (LYR motif-containing protein 6) (NADH-ubiquinone oxidoreductase B14 subunit)
- B14
- LYRM6
- CI-B14
- NADHB14
- Gene biotype
- Protein coding
- Gene family
- LYR motif containing|NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 137.05
- Tissue specificity (Gini)
- 0.162
- Tissue specificity (tau)
- 0.497
- KEGG gene identifiers
- hsa:4700
- Protein interaction confidence
- 0.92493
- Protein interaction partners
- 115
- R-HSA-611105
- R-HSA-6799198
- End position
- 42090884
- Start position
- 42085526
- Chromosome
- 22
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- End piece
- Mid piece
- Nucleoplasm
- Vesicles
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.497185
- Expression inequality (Gini)
- 0.16224
Expression in transcripts per million
- Heart - Left Ventricle
- 137.05
- Muscle - Skeletal
- 122.61
- Heart - Atrial Appendage
- 121.91
- Kidney - Medulla
- 116.49
- Esophagus - Muscularis
- 101.59
Expression in transcripts per million
- Heart - Left Ventricle137.05
- Muscle - Skeletal122.61
- Heart - Atrial Appendage121.91
- Kidney - Medulla116.49
- Esophagus - Muscularis101.59
- Colon - Sigmoid99.57
- Brain - Cerebellar Hemisphere94.99
- Esophagus - Gastroesophageal Junction94.48
- Cells - EBV-transformed lymphocytes92.77
- Brain - Cerebellum85.55
- Colon - Transverse82.02
- Brain - Frontal Cortex (BA9)80.45
- Cells - Cultured fibroblasts79.9
- Artery - Tibial75.95
- Adrenal Gland73.03
- Kidney - Cortex72.94
- Thyroid72.45
- Pituitary72.24
- Stomach70.6
- Artery - Coronary70.1
- Cervix - Ectocervix68.91
- Bladder68.72
- Esophagus - Mucosa68.03
- Brain - Cortex67.45
- Artery - Aorta67.19
And 29 more, listed on the interactive page.
Biological processes
- GO:0032981
- GO:0005739
- GO:0005743
- GO:0031966
- GO:0045271
Molecular functions
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor